Medivation Presents New Data on Dimebon's Novel Mechanism...(otentialbenefits of Dimebon as a treatme...)

Date:12/9/2008

otential benefits of Dimebon as a treatment for Alzheimer's disease and Huntington's disease and future clinical development plans and milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, including Medivation's collaborative relationship with Pfizer, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q filed on November 10, 2008, with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

'/>"/>

SOURCE Medivation, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
2. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
3. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
4. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
5. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
8. Medivation Announces Participation in Upcoming Conferences
9. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
11. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5